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Introduction
Clinicians regularly face situations with two or more 
alternative actions. Each alternative often has different 
advantages and disadvantages, including differences in 
effectiveness, adverse effects, costs and other factors 
(criteria). To make these choices, clinicians rely on rec-
ommendations from clinical practice guidelines,1  other 
recommendations (such as from colleagues or experts) 
or implicit rules for decision making, such as based on 
their personal experience or what others do. To ensure 
trustworthiness, clinical practice guidelines are made 
by groups of people (guideline panels) with relevant 
skills, perspectives, and knowledge; they are informed 
by the best available evidence; and they are systemati-
cally developed.1-4
In the first article in this series, we described GRADE 
Evidence to Decision (EtD) frameworks and their 
 rationale for different types of decisions.5 In this second 
article, we describe the use of EtD frameworks for clini-
cal recommendations and how they can help clinicians 
and patients who use those recommendations.
We will use the scenario in box 1 to illustrate the use 
of EtD frameworks for clinical recommendations.6-8  The 
question posed for the panel in this scenario was: 
“Should patients with atrial fibrillation and a moderate 
to high risk of stroke who are currently taking warfarin 
switch to dabigatran?” The panel specified the question 
details, including the population, intervention, com-
parison, and outcomes (PICO),9 the setting for which 
the recommendation is intended, and the perspective 
they have taken (box 2).
The EtD framework for clinical recommendations 
was developed as part of the DECIDE project, using an 
iterative process.10-12  The starting point for EtD frame-
works for clinical recommendations was the GRADE 
Working Group’s approach for going from evidence to 
clinical recommendations.13-15  We further developed 
the EtD framework for clinical recommendations 
based on reviews of relevant literature and hand-
books for clinical guidelines, brainstorming and dis-
cussion by the authors, feedback from stakeholders, 
user testing, and application of the framework to a 
range of recommendations in workshops and real 
guidelines. Detailed methods used to develop EtD 
frameworks are available in the DECIDE project proto-
col.10 Appendix 1 is a glossary of terminology used in 
EtD frameworks.
The general structure of EtD frameworks is the same 
for clinical recommendations, coverage decisions, and 
health system or public health recommendations and 
decisions.5 The EtD frameworks include three main sec-
tions: formulating the question, assessing the evidence 
and additional considerations for each criterion, and 
drawing conclusions. Appendix 2 is an example an EtD 
framework for the scenario in box 1. In this article we 
focus on elements of EtD frameworks for clinical recom-
mendations that are of particular relevance to clini-
cians and patients.
Formulating the question
When formulating the relevant questions, panels 
should specify the patients, intervention, comparison, 
and outcomes (PICO),9 their perspective, subgroups for 
which the evidence and their judgments and recom-
mendation might differ from an overall recommenda-
tion, and the settings for which the recommendation is 
intended.
Summary poIntS
•	 Clinicians	do	not	have	the	time	or	resources	to	consider	the	underlying	evidence	
for	the	myriad	decisions	they	must	make	each	day	and,	as	a	consequence,	rely	on	
recommendations	from	clinical	practice	guidelines
•	 Guideline	panels	should	consider	all	the	relevant	factors	(criteria)	that	influence	
a	decision	or	recommendation	in	a	structured,	explicit,	and	transparent	way	and	
provide	clinicians	with	clear	and	actionable	recommendations
•	 The	GRADE	working	group	has	developed	Evidence	to	Decision	(EtD)	frameworks	
for	different	types	of	decisions	and	recommendations.
•	 The	purpose	of	the	Evidence	to	Decision	(EtD)	frameworks	is	to	help	groups	of	
people	(panels)	use	evidence	in	a	structured	and	transparent	way	to	inform	
decisions	in	the	context	of	clinical	recommendations,	coverage	decisions,	and	
health	system	or	public	health	recommendations	and	decisions.	In	this	article	we	
will	describe	EtD	frameworks	for	clinical	practice	recommendations
•	 The	general	structure	of	the	EtD	framework	for	clinical	recommendations	is	
similar	to	EtD	frameworks	for	other	types	of	recommendations	and	decisions,	and	
includes	formulation	of	the	question,	an	assessment	of	the	different	criteria,	and	
conclusions
•	 Clinical	recommendations	require	considering	criteria	differently,	depending	on	
whether	an	individual	patient	or	a	population	perspective	is	taken.	For	example,	
from	an	individual	patient’s	perspective,	out-of-pocket	costs	are	an	important	
consideration,	whereas,	from	a	population	perspective,	resource	use	(not	only	
out-of-pocket	costs)	and	cost	effectiveness	are	important	
•	 From	a	population	perspective,	equity,	acceptability,	and	feasibility	are	also	
important	considerations,	whereas	the	importance	of	these	criteria	is	often	
limited	from	an	individual	patient	perspective
•	 Specific	subgroups	for	which	different	recommendations	may	be	required	should	
be	clearly	identified	and	considered	in	relation	to	each	criterion	because	
judgments	might	vary	across	subgroups
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Guideline panels are often not explicit about the per-
spective they are taking. This can lead to confusion 
and, sometimes, to inappropriate recommendations. 
For example, from an individual patient perspective, 
whether the net desirable effect of an intervention, 
such as dabigatran, is worth the out-of-pocket costs 
can be critical for making a decision. This can be an 
issue if the government or insurance does not pay the 
full cost of the drug or if coverage is restricted. Total 
resource requirements (outside of out-of-pocket costs), 
cost effectiveness (from a population perspective), and 
impacts on equity are unlikely to be critical for per-
sonal choices. However, from a population perspective, 
such as the one taken by the National Institute for 
Health and Care Excellence (NICE), decisions affect 
how limited healthcare resources are used. Total 
resource requirements, cost effectiveness (from a 
broader perspective than that of individual patients), 
equity, acceptability, and feasibility considerations 
can drive a recommendation.
Consideration of different perspectives can lead to 
formulation of different recommendations. For exam-
ple, taking a population perspective, a panel might rec-
ommend restricted use of new anticoagulants for 
patients with atrial fibrillation because of their large 
costs and a small increase in desirable health effects for 
patients who are already well controlled with warfarin 
(the comparator). In contrast, taking an individual per-
spective in the context of small out-of-pocket costs (for 
patients with insurance that pays most or all of the cost 
of the new anticoagulants), a panel might recommend 
new anticoagulants because they are less burdensome 
than warfarin, which requires daily medication, life-
style limitations, dietary restrictions, and frequent 
blood tests and clinic visits.
The remit of the organisation making a recommenda-
tion usually determines the specific perspective that a 
panel takes. For example, a national guideline devel-
oper, such as NICE, might take the perspective of the 
government or the department of health, given its man-
date to ensure optimal use of the health budget in the 
country. A professional society, on the other hand, 
might take an individual patient perspective with a 
view towards providing guidance to individual patients 
and clinicians making individual patient choices.
Recommendations can differ across subgroups of the 
population originally considered when formulating the 
question. This may be due to differences in people (such 
as differences in baseline risk as assessed by the 
CHADS2 score), differences in interventions (such as dif-
ferent doses or different drugs within the same class), 
differences in comparisons (such as different levels 
of  international normalised ratio (INR) control with 
 warfarin), or different settings (such as differences in 
access to a thrombosis clinic).16  For the question in box 
2, the panel paid particular attention to patients with 
good INR control. The rationale for this is that patients 
taking warfarin with good INR control have better out-
comes than patients with poor INR control, and, conse-
quently, the desirable health effects of dabigatran 
compared with warfarin are less.16
assessing the criteria considered
EtD frameworks for clinical recommendations from a 
population perspective include 12 criteria. For recom-
mendations from an individual patient perspective, 
some criteria differ in how they are applied (table 1). 
The technical team or panel may use research evidence 
from systematic reviews or single studies to inform 
judgments about the effects of the intervention and 
other criteria. For example, they might use an epidemi-
ological study of the baseline risk for an outcome in the 
setting(s) of interest, a systematic review or, occasion-
ally, a single study of the effects of an intervention when 
that is all that is available, a systematic review or a sin-
gle study of how much people value the relevant out-
comes, or an economic analysis.
The source of the evidence summarised in the frame-
work should be referenced, and any limitations of how 
Box 1: Clinical scenario
Warfarin	reduces	the	risk	for	ischaemic	stroke	in	patients	with	atrial	fibrillation,	but	
increases	the	risk	for	haemorrhage	and	requires	frequent	blood	tests	and	clinic	visits	
to	monitor	the	international	normalised	ratio	(INR)	and	adjust	the	dose.	Apixaban,	
dabigatran,	and	rivaroxaban	are	new,	fixed-dose,	oral	anticoagulants,	each	of	which	
has	been	compared	with	warfarin	in	randomised	trials.6-8
Dabigatran	is	a	direct	thrombin	inhibitor.	The	RE-LY	(Randomized	Evaluation	of	
Long-Term	Anticoagulation	Therapy)	trial	was	an	international,	multicentre,	
randomised	trial	in	which	18	113	patients	with	atrial	fibrillation	at	increased	risk	for	
stroke	(CHADS2	score	≥1)	were	randomly	assigned	to	receive	low	dose	dabigatran	
(110	mg	twice	daily),	high	dose	dabigatran	(150	mg	twice	daily),	or	adjusted	dose	
warfarin.6	The	median	follow-up	was	two	years.	Outcomes	were	better	with	the	higher	
dose	of	dabigatran.
A	guideline	panel	from	a	national	health	system	guideline	programme	is	faced	with	
the	question:	“Should	dabigatran	or	warfarin	be	used	for	atrial		fibrillation	in	patients	
with	a	moderate	to	high	risk	of	stroke?”
Box 2: Evidence to Decision (EtD) framework—Question formulation section*
Should	patients	with	atrial	fibrillation	and	a	moderate	to	high	risk	of	stroke	who	are	
currently	taking	warfarin	switch	to	dabigatran?
Problem:	Patients	with	atrial	fibrillation	and	a	moderate	to	high	risk	of	stroke	taking	
warfarin
Intervention:	Dabigatran	(150	mg)	daily
Comparison:	Warfarin
Main outcomes:	Death,	stroke,	major	bleeding,	myocardial	infarction,	treatment	
burden
Setting:	High	resource	setting
Perspective:	Health	system
Subgroups:	Patients	who	are	well	controlled	with	warfarin
Background:	Warfarin	reduces	the	risk	for	ischaemic	stroke	in	patients	with	atrial	
fibrillation	but	increases	the	risk	for	haemorrhage	and	requires	frequent	blood	tests	
and	clinic	visits	to	monitor	the	international	normalised	ratio	(INR)	and	adjust	the	
dose.	Apixaban,	dabigatran,	and	rivaroxaban	are	new,	fixed-dose,	oral	anticoagulants,	
each	of	which	has	been	compared	with	warfarin	in	randomised	trials.6-8
Dabigatran	is	a	direct	thrombin	inhibitor.	The	RE-LY	(Randomized	Evaluation	of	
Long-Term	Anticoagulation	Therapy)	trial	was	an	international,	multicentre,	
randomised	trial	in	which	18	113	patients	with	atrial	fibrillation	at	increased	risk	for	
stroke	(CHADS2	score	≥1)	were	randomly	assigned	to	receive	low	dose	dabigatran	
(110	mg	twice	daily),	high	dose	dabigatran	(150	mg	twice	daily),	or	adjusted	dose	
warfarin.6	The	median	follow-up	was	two	years.	Outcomes	were	better	with	the	higher	
dose	of	dabigatran.
*Templates	used	for	EtD	frameworks	are	adapted	for	specific	types	of	decisions.	The	one	shown	here	
is	for	a	clinical	recommendation	from	a	population	perspective.
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the evidence was summarised should be noted, partic-
ularly when the source is not a systematic review. If the 
technical team does not find any evidence for a crite-
rion, they should note the lack of evidence and include 
any relevant information or assumptions used to make 
a judgment under “Additional considerations.”
Technical teams or panels can reduce the burden of 
preparing frameworks. For example, in a guideline it is 
often the case that individual systematic reviews 
answer one or more criteria across several EtD frame-
works. They can duplicate frameworks electronically,5 
avoiding the need to replicate work. In other instances, 
it can be clear from early in the evidence synthesis that 
it is unnecessary to review the evidence for some crite-
ria. For example, if there is high certainty evidence for 
large harms and small benefits, the direction and 
strength of a recommendation might be clear, making it 
unnecessary to review the evidence for the rest of the 
criteria. This can also work in the opposite direction. 
For example, a panel charged with making recommen-
dations for funding of health technologies recently con-
sidered faecal microbiota transplantation for recurrent 
Clostridium difficile infection. The overwhelming evi-
dence of large benefit for this extremely serious, costly 
condition with minimal adverse effects made detailed 
consideration of other criteria unnecessary. Under such 
circumstances, panels can then rapidly consider the 
rest of the criteria without systematically reviewing the 
evidence and provide their rationale under “Additional 
considerations.”
Additional considerations can include:
•	 Other evidence, such as estimates from routinely col-
lected data
•	 Plausible consequences for which no evidence was 
found (such as logical reasons for anticipating a 
potential reduction in inequities) or plausible rea-
sons for anticipating that the intervention (option) 
might not be acceptable to key stakeholders or might 
be difficult to implement
•	 Any assumptions that were made and, if relevant, the 
basis for those assumptions
•	 Explanations of the basis for a judgment, if a judg-
ment does not flow directly from the research evi-
dence (such as the logic underlying a judgment 
about the balance between desirable and undesir-
able effects)
•	 Documenting voting results or relevant discussions 
by the panel.
Is the problem a priority?
The more serious a problem is, the more likely it is that 
an intervention that addresses the problem should be a 
priority or should be recommended (if it is effective with 
minimal harms or burden). For example, from a popula-
tion perspective, helpful interventions for conditions 
that are fatal or disabling are likely to be a higher prior-
ity, and to be recommended, than the ones for transient 
conditions or those that cause only minor and reversible 
distress. Panels might decide that all of the problems 
that a particular guideline addresses are equally import-
ant as part of a prioritisation process, making this crite-
rion irrelevant. They might also argue that, from an 
individual patient perspective, the importance of the 
problem is not relevant (if the patient has a condition 
and wants to do something about it, it will always be a 
priority). For instance, a panel considered the use of 
ultrasound scanning as a complement to mammogra-
phy in women at high risk of breast cancer (1% of 
women) in whom magnetic resonance imaging (the 
complementary imaging procedure of choice) was con-
traindicated (a very small proportion of high risk 
women). Although this affects only a very small group of 
women, the issue is highly relevant to that population.
However, the importance of a problem can some-
times affect decisions made by individual patients. For 
example, patients’ priorities for primary prevention 
might affect the strength of recommendations, as some 
problems (risks) might be more important than others, 
or patients’ baseline risk might be so low that preven-
tion would not be a priority, even if it was effective. Sim-
ilarly, patients with comorbidities and their carers 
might need to consider a number of different treatments 
and might need to prioritise these based on how import-
ant the problems are.
How substantial are the desirable and undesirable 
anticipated effects?
Summaries of findings, such as fig 1 , provide estimates 
of the effects of the interventions being compared on 
Table 1 | Criteria for clinical recommendations from a population and an individual patient perspective
Population perspective Individual patient perspective
Is the problem a priority (from a population perspective)? Is the problem a priority (from the perspective of individual patients)?
How substantial are the desirable anticipated effects?
How substantial are the undesirable anticipated effects?
What is the overall certainty of the evidence of effects?
Is there important uncertainty about or variability in how much people value the main outcomes?
Does the balance between desirable and undesirable effects favour the intervention or the comparison?
How large are the resource requirements (costs)? Does the cost effectiveness of the intervention (the out-of-pocket 
cost relative to the net desirable effect) favour the intervention or the 
comparison?
What is the certainty of the evidence of resource requirements (costs)?
Does the cost effectiveness of the intervention favour the intervention or the comparison?
What would be the impact on health equity?
Is the intervention acceptable to key stakeholders? Is the intervention acceptable to patients, their care givers, and 
healthcare providers?
Is the intervention feasible to implement? Is the intervention feasible for patients, their care givers, and 
healthcare providers?
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the outcomes of interest. While this summary is based 
on a systematic review that identified a single large 
study, a typical summary of findings is based on sys-
tematic reviews of multiple studies.17
The more substantial the desirable effects, the more 
likely it is that an intervention should be recommended. 
Conversely, the more substantial the undesirable effects 
(including the relative burden of interventions), the less 
likely it is that an intervention should be recommended. 
Judgments about how substantial effects are should 
take into account the absolute magnitude of the effect 
(such as the proportion of people who would benefit) 
and the importance of the outcome (such as how much 
it is valued by the people affected).
What is the overall certainty (quality) of the 
evidence of effects?
The less certain the evidence is for the main outcomes 
(desirable and undesirable effects, including the bur-
den), the less likely it is that a strong recommendation 
(appendix 1) should be made for an intervention, and 
the more likely it is that the intervention should be eval-
uated, if implemented.18 19
In the scenario in box 1, the overall certainty of the 
evidence (the lowest certainty for the outcomes that are 
critical for a decision) is moderate, primarily because of 
risk of bias (table 2 ). The certainty of the evidence for 
the effect in well controlled patients was considered 
low because of imprecision in addition to risk of bias 
(fig 2 ). Factors that should be assessed when evaluating 
the certainty of the evidence for each outcome include 
risk of bias, inconsistency, indirectness, imprecision, 
and publication bias.18 19  Although the certainty of the 
evidence was low for this subgroup of patients, the 
panel judged that the subgroup effect was credible20—
that is, that the subgroup estimates provided a better 
basis for decision making than the overall estimates.
Is there important uncertainty about or variability in 
how much people value the main outcomes?
Typically, people place a higher value on avoiding a 
stroke than on avoiding serious gastrointestinal bleed-
ing (box 3). Uncertainty about how much those 
affected (patients or their carers) value the outcomes 
of interest can be a reason to make a weak (conditional) 
rather than a strong recommendation (appendix 1). 
Variability in how patients value the main outcomes 
(to the extent that individuals with different values 
would make different decisions) is another reason for 
a weak recommendation. For example, some patients 
might place a lower value on avoiding a stroke 
 compared with avoiding serious gastrointestinal 
bleeding or the burden of warfarin treatment than 
other patients.
A systematic review found that there is moderate 
certainty of the evidence that typical patients place 
approximately three times more value on avoiding a 
stroke than on avoiding major gastrointestinal 
Fig 1 | “Summary of findings” table: dabigatran versus warfarin for atrial fibrillation.4 An interactive version of this table is 
at http://isof.epistemonikos.org/#finding/5377108ff30d0c7233205f13
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bleeding,21  and moderate variability in values across 
patients. In the dabigatran scenario it is uncertain 
whether patients who are well controlled with warfa-
rin would value avoiding the burden of taking warfa-
rin more than the possible downsides of switching to 
dabigatran. There is probably important variability 
in how much value patients place on avoiding the 
burden of warfarin; that is, it is likely that some 
patients would choose to switch and others would 
choose not to switch based on the burden of taking 
warfarin. Similarly, 40-50 year old women might 
make different choices about breast cancer screen-
ing because of differences in how averse they are to 
the undesirable effects and burden of screening 
mammography.22  23
Does the balance between the desirable and 
undesirable effects favour the intervention or the 
comparison?
Judgments about the balance between the desirable 
and undesirable effects need to take into account 
the preceding four judgments (the magnitude of the 
desirable and undesirable effects, the certainty of the 
evidence of effects, and how much those affected 
value the outcomes). In the scenario in box 1, the 
panel decided that the balance of desirable and 
undesirable effects probably favours dabigatran (fig 1 
and table 2 ). However, the balance is less clear for 
the subgroup of patients who are well controlled with 
warfarin. These patients would have similar out-
comes, apart from the greater burden of taking warfa-
rin compared with dabigatran (fig 2 ).6 16 For this 
subgroup, panels might be more inclined to judge the 
balance as probably favouring warfarin or not favour-
ing either option. Uncertainty about potential 
adverse effects of dabigatran and compliance with 
taking the drug could increase uncertainty about the 
balance between the desirable and undesirable 
effects (appendix 2).
How large are the resource requirements (costs)?
The greater the cost, the less likely it is that an inter-
vention will be recommended. If resource use is 
 considered to be critical to a decision about a recom-
mendation the more likely it is that resource use 
should be formally evaluated. Which costs and sav-
ings are included depend on the perspective that is 
taken.
In the dabigatran example, for an estimated 
66 000 patients with atrial fibrillation, dabigatran 
was estimated to cost €30 million per year more than 
warfarin, considering both the cost of the drugs and 
clinic visits for monitoring. The difference in the 
estimated lifetime cost of the two drugs, for a popu-
lation of 66 000 patients, was €308 million more for 
dabigatran.24 From an individual perspective the 
costs depend on how much the target population is 
likely to pay out-of-pocket. This might be all the cost 
(if dabigatran is not covered by insurance), a propor-
tion (if it is partially covered) or nothing (if it is fully 
covered).T
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What is the certainty (quality) of the evidence of 
resource requirements (costs)?
If resource use is considered to be critical for a recom-
mendation, the less certain the evidence is for 
resource requirements, the less likely it is that a panel 
should make a strong recommendation for or against 
an intervention. Judgments about the certainty of the 
evidence for resource requirements are similar to 
judgments about the evidence of effects.25 In the 
 scenario in box 1, there is important uncertainty 
about resource use for dabigatran and other new anti-
coagulants (appendix 2).
Does the cost effectiveness of the intervention 
favour the intervention or the comparison?
The greater the cost in relation to the net benefit, the 
less likely it is that an intervention should be recom-
mended. Judgments about the cost effectiveness of an 
intervention need to take into account several criteria, 
including
•	 The balance between the desirable and undesirable 
effects (the net benefit), the certainty of the evidence 
of effects, and uncertainty about or variability in how 
much people value the main outcomes
•	 Resource requirements (costs) and uncertainty about 
the costs.
Several economic evaluations have assessed the cost 
effectiveness of dabigatran for stroke prevention in 
atrial fibrillation patients in different settings.26  These 
models generally found dabigatran to be cost effective, 
but the incremental cost effectiveness ratios (ICERs) 
varied considerably between them (appendix 2). In a 
Norwegian economic evaluation, the ICER was less 
than a suggested threshold of €70 000 per quality 
adjusted life year in 80% of simulations. It was not cost 
effective for the subgroup of patients who are well 
Box 3: Expressing the importance (value) of outcomes as a measure of utility 
(or disutility)
•	One	way	of	expressing	the	value	of	a	health	state	is	to	use	utility	values,	a	measure	
the	strength	of	the	preference	people	have	for	a	specific	health	state,	from	zero	(for	
death)	to	one	(for	perfect	health)
•	A	disutility	is	a	reduction	in	utility.	For	example,	a	severe	stroke	might	have	a	utility	
value	of	0.10,	which	is	a	reduction	or	disutility	of	0.90	compared	with	being	healthy,	
a	minor	stroke	might	have	a	utility	value	of	0.75	(a	disutility	of	0.25),	and	a	serious	
gastrointestinal	bleed	a	utility	value	of	0.90	(a	disutility	of	0.10)
•	Such	values	indicate	that	the	relative	importance	of	a	severe	stroke	(or	how	much	
people	value	avoiding	a	severe	stroke)	is	more	than	that	of	a	minor	stroke,	which	is	
more	than	that	of	a	gastrointestinal	bleed
•	Evidence	about	utilities	can	come	from	studies	that	have	measured	utility	values	or,	
ideally,	from	systematic	reviews	of	those	studies.	Evidence	can	also	come	from	
studies	that	directly	measure	the	choices	people	make	when	presented	with	the	
probabilities	of	the	desirable	and	undesirable	effects,	a	description	of	those	
outcomes	(health	states),	and	information	about	when	they	would	occur	and	how	
long	they	would	last.	Qualitative	research	evidence	can	also	sometimes	inform	
judgments	about	how	much	people	value	different	outcomes
Fig 2 | Summary of findings: patients who are well controlled taking warfarin.14 An interactive version of this table is at 
http://isof.epistemonikos.org/#finding/537730b3f30d0c7233205f14
the bmj | BMJ 2016;353:i2089 | doi: 10.1136/bmj.i2089
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 controlled with warfarin, or overall for thresholds 
below €38 000 (2012 Euros).24
In addition, if a cost effectiveness ratio from a formal 
economic evaluation is used, panels also should con-
sider how robust the estimate is when single or multiple 
variables in the model are varied (one-way and 
multi-variable sensitivity analyses), whether the eco-
nomic evaluation is reliable, and if a published eco-
nomic evaluation was used, how applicable it is for the 
setting(s) of interest.
What would be the impact on health equities?
Interventions that reduce inequities are more likely to be 
recommended than ones that do not (or ones that 
increase inequities).27 28 In the dabigatran example, the 
panel considered that dabigatran might reduce inequities 
for people who do not have easy access to INR testing, 
although there was no direct research evidence for this.
Is the intervention acceptable to key stakeholders?
The less acceptable an intervention is to key stake-
holders (including patients), the less likely it is that it 
should be recommended, or if it is recommended, the 
more likely it is that an implementation strategy 
might be needed to address concerns about accept-
ability. An intervention might be unacceptable due to 
the distribution of the desirable and undesirable 
effects and costs; that is, who benefits (or who is 
harmed) and who pays (or saves). For example, peo-
ple who would have increased costs or burdens with-
out experiencing the benefits of an intervention might 
find this unacceptable.
Disagreement about ethical principles (such as 
autonomy, non-maleficence, beneficence, or justice) is 
another reason why some stakeholders might find an 
intervention unacceptable.29 30 Some ethical consider-
ations, such as autonomy, may be important enough to 
some organisations or panels that they might elect to 
consider these separately, either as a detailed judgment 
or as a criterion.
In the dabigatran example, some patients and clini-
cians might also be opposed to restrict its use. These are 
unlikely to be reasons not to restrict the use of dabiga-
tran but might be important implementation consider-
ations.
Is the intervention feasible to implement?
The less feasible (capable of being accomplished or 
brought about) an intervention is, the less likely it is 
that it should be recommended to clinicians. Barriers to 
implementing an intervention can also modify the 
strength of a recommendation. Clinicians might find it 
unhelpful to receive strong recommendations if the 
interventions are not implementable in their settings. 
However, if the target audience is policymakers, a panel 
might want to make a strong recommendation, despite 
barriers that currently make it difficult or impossible for 
clinicians to adhere to the recommendation. Panels can 
also incorporate consideration of critical barriers, such 
as the availability of the intervention, directly into their 
recommendations. More commonly, panels can assist 
those responsible for implementing recommendations 
by addressing key barriers to implementing their rec-
ommendation in their conclusions.31
putting it all together
How important each of the above criteria is for a recom-
mendation can vary. To make a recommendation, a 
panel must consider the implication and importance of 
each of the above judgments. In many cases, this will be 
straightforward and not require detailed consideration. 
However, when there is uncertainty or disagreement, it 
can help to explicitly consider this for each criterion.
Based on their overall assessment across criteria, 
panels must reach a conclusion about the direction of 
their recommendation (for or against the intervention) 
and the strength of their recommendation.13 14 They 
should provide a justification for their recommenda-
tion, based on the criteria used in their assessment. 
They can reach these conclusions in different ways, 
including using informal or formal consensus processes 
or voting. For straightforward recommendations, infor-
mal consensus processes are often sufficient.
In the dabigatran example, the panel made a weak 
recommendation in favour of switching to dabigatran 
only for patients who are not well controlled with war-
farin despite good adherence. Their concern about the 
cost of dabigatran (from a population perspective) and 
uncertainty about the balance of the desirable and 
undesirable effects (including uncertainty about the 
risk of rare severe adverse effects) was the reason for 
their making a weak recommendation. The panel 
made  a weak (conditional) recommendation against 
Box 4: Justification and detailed justification of a strong and a conditional 
recommendation
Strong recommendation
The	guideline	panel	recommends	in	favour	of	oral	anticoagulation	rather	than	aspirin	
for	patients	with	atrial	fibrillation	who	are	at	high	risk	of	stroke	(such	as	CHADS2 score 
≥2).
Justification—In	patients	with	atrial	fibrillation	with	a	high	risk	of	stroke	(such	as	
CHADS2 score ≥2)	the	reduction	in	the	number	of	strokes	outweighs	the	increase	in	
the	number	of	additional	non-fatal	major	extracranial	bleeds	and	the	burden	of	oral	
anticoagulation,	and	oral	anticoagulation	is	cost	effective.	Therefore,	the	panel	made	
a	strong	recommendation	in	favour	of	oral	anticoagulation	rather	than	aspirin	for	
patients	with	a	high	risk	of	stroke.
Conditional recommendation
For	patients	with	atrial	fibrillation	who	have	a	moderate	to	high	risk	of	stroke	
(CHADS2 score ≥1)	the	guideline	panel	suggests	they	should	switch	to	dabigatran	
only	if	they	are	not	well	controlled	with	warfarin,	despite	good	adherence	(conditional	
recommendation,	moderate	certainty	of	the	evidence).
Justification—Overall,	and	particularly	for	patients	who	are	not	well	controlled	with	
warfarin,	the	balance	of	desirable	and	undesirable	effects	favours	dabigatran.	
However,	the	panel	made	a	weak	(conditional)	recommendation	in	favour	of	switching	
to	dabigatran	for	patients	who	are	not	well	controlled	with	warfarin	because	of	
concerns	about	the	cost	of	dabigatran	(from	a	population	perspective)	and	
uncertainty	about	the	balance	of	the	desirable	and	undesirable	effects	(including	
uncertainty	about	the	risk	of	rare	severe	adverse	effects).	The	panel	made	a	weak	
(conditional)	recommendation	against	switching	to	dabigatran	for	patients	who	are	
well	controlled	with	warfarin	because	there	may	be	little	or	no	reduction	in	the	risk	of	
strokes	and	warfarin	is	cost	effective	compared	with	dabigatran	for	these	patients,	
but	warfarin	treatment	might	be	very	burdensome	for	some	patients.
doi: 10.1136/bmj.i2089 | BMJ 2016;353:i2089 | the bmj
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 switching to dabigatran for patients who are well con-
trolled with warfarin because there may be little or no 
reduction in the risk of strokes and warfarin is cost 
effective compared with dabigatran for these patients, 
but warfarin treatment might be very burdensome for 
some patients. A justification summarises the panel’s 
judgments for each of the criteria that were most 
important for their decision (box 4).
In another scenario a panel made a strong recom-
mendation in favour of oral anticoagulation rather than 
aspirin for patients with atrial fibrillation who are at 
high risk of stroke (such as CHADS2 score ≥2). The panel 
was confident that the reduction in the number of 
strokes clearly outweighed the number of additional 
non-fatal major extracranial bleeds, and made a strong 
recommendation on this basis (box 4).
The panel’s conclusions about implementation 
considerations should specify key concerns about the 
feasibility and acceptability of the intervention and 
strategies to address those concerns. For example, if 
the panel recommended limiting the use of dabiga-
tran to patients who are not well controlled with 
 warfarin, it might anticipate that this would be unac-
ceptable to some key stakeholders, including the 
pharmaceutical company, some clinicians, and some 
patients. In this case, it might be important to be pre-
pared to address objections raised by those stake-
holders. In addition, it might be important to consider 
strategies to ensure that dabigatran is prescribed only 
to those patients.
Finally, panels can specify any indicators that 
should be monitored, when the recommendation is 
implemented, and priorities for further research to 
address important uncertainties (appendix 2).32 For 
example, given that there is uncertainty about the 
costs and possible adverse effects of dabigatran, and 
potential concerns about adherence to the recom-
mendation, it might be important to monitor and 
evaluate these.
Final remarks
EtD frameworks for clinical practice recommendations 
provide a structured and transparent approach for 
guideline panels. The framework helps ensure consid-
eration of key criteria that determine whether an inter-
vention should be recommended and that judgments 
are informed by the best available evidence. Frame-
works are also a way for panels to make guideline users 
aware of the rationale (justification) for their recom-
mendations.
Feedback from workshops and use of EtD frame-
works by guideline panels has been uniformly positive. 
The most important concern that has been raised about 
EtD frameworks by guideline developers is that they are 
complex and require additional resources for prepara-
tion. Similar concerns have been raised about the com-
plexity of other elements of the GRADE approach to 
making judgments about the certainty of evidence and 
strength of recommendations. It is, however, the judg-
ments themselves that are complex, not the GRADE 
approach or EtD frameworks.
The challenge faced by GRADE or any other approach, 
is to keep the approach to making these judgments as 
simple as possible, but no simpler. While it might be 
possible not to consider some criteria, there is a risk of 
ignoring potentially important criteria that panels 
should take into account when making a recommenda-
tion. However, guideline panels need to make prag-
matic decisions. For example, it is not always possible 
to undertake a full economic evaluation or to conduct 
systematic reviews for each criterion for which this 
might be relevant. Nor is it always necessary. Use of EtD 
frameworks does not require this, but they do require 
transparent consideration of which judgments are 
important for a recommendation and what evidence is 
used to inform each judgment.
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